

PFIZER

**Pharmacia Corporation
Of Pfizer, Inc.
Patent Department
575 Maryville Centre Drive
St. Louis, MO 63141**

**Karol J. Wilder
Senior Patent Paralegal
Tel: 314-274-9091
Fax: 314-274-7256**

facsimile transmittal

To: Nadine Clark - USPTO - Initial Examination

Fax: 571-270-9869

Pages: 5 (+ cover)

Phone: 703-308-9250 XT. 144

Date: 23 JAN 2007

Re: Our Case: PHA01640/0/US (App. No. 10/808,146)

CC:

X Urgent **For Review** **Please Comment** **Please Reply** **Please Recycle**

Comments: Dear Ms. Clark,

This responds to your telephone message of 23 Jan 07 to Julie M. Lappin, Esq. Pursuant to your request, attached please find a duly executed Part B Fee Transmittal for the above-subject case. Additionally, attached are four pages indicating Electronic Patent Application Fee Transmittal and Electronic Acknowledgement Receipt to further indicate proper, timely filing. We are confident these documents will provide you with the information necessary to advance this application to issue. If you need any additional information, please let us know. Thank you.

Regards,

Karol Wilder

THIS FACSIMILE MESSAGE IS CONFIDENTIAL
AND MAY CONTAIN PRIVILEGED INFORMATION

If you are not the intended recipient, you are hereby notified
that any use, copying or dissemination of this material
is prohibited. Please notify us at the number listed above
and destroy the original message. Thank you.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax **(571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Use Block 1 for any change of address)

7390 07/11/2006

Pharmacia Corporation
 Corporate Patent Department
 P.O. Box 1027
 Chesterfield, MO 63006

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
 I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Karol J. Wilder

(Depositor's name)

(Signature)

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/88,146	03/24/2004	Richard C. Durley	PHA-01640/0/US	3007

TITLE OF INVENTION: SUBSTITUTED PYRIMIDINONES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$300	\$0	\$1700	10/11/2006

EXAMINER	ART UNIT	CLASS-SUBCLASS
RAO, DEEPAK R	1624	514-269000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev. 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list
 (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
 (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

Julie M. Lappin
 2 _____
 3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

PHARMACIA CORPORATION (of Pfizer, Inc.) P.O. Box 1027 Chesterfield, MO 63006 USA

Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government

4a. The following fee(s) are submitted:

Issue Fee
 Publication Fee (No small entity discount permitted)
 Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid Issue fee shown above)

A check is enclosed.
 Payment by credit card. Form PTO-2038 is attached.
 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 16-1445 (enclose an extra copy of this form).


5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature



Date July 13, 2006

Typed or printed name

Julie M. Lappin, Esq.

Registration No. 46,612

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

07/13/2006	00001522	4	1501	\$1,400.00	07/13/2006	DA 191025	
PTOL-E	07/13/2006	00001523	4	1504	\$300.00	07/13/2006	DA 191025 ERCE

Electronic Acknowledgement Receipt

EFS ID:	1111425		
Application Number:	10808146		
Confirmation Number:	3007		
Title of Invention:	SUBSTITUTED PYRIMIDINONES		
First Named Inventor:	Richard C. Durley		
Correspondence Address:	Pharmacia Corporation Corporate Patent Department P.O. Box 1027 Chesterfield MO 63006 US 3142747256		
Filer:	Julie Marie Chappell		
Filer Authorized By:			
Attorney Docket Number:	PHA-01640/0/US		
Receipt Date:	13-JUL-2006		
Filing Date:	24-MAR-2004		
Time Stamp:	11:54:13		
Application Type:	Utility		
International Application Number:			

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$1700

MAIN COMMUNICATION NUMBER	
Deposit Account	670 191025
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Fee Worksheet (PTO-875)	fee-info.pdf	8256	no	2
Warnings:					
Information:					
		Total File Size (in bytes):	8256		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

Electronic Patent Application Fee Transmittal																																												
Application Number:	10808146																																											
Filing Date:	24-Mar-2004																																											
Title of Invention:	SUBSTITUTED PYRIMIDINONES																																											
First Named Inventor:	Richard C. Durley																																											
Filler:	Julie Marie Chappell																																											
Attorney Docket Number:	PHA-01640/0/US																																											
Filed as Large Entity																																												
Utility Filing Fees <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Description</th> <th style="text-align: left; padding: 2px;">Fee Code</th> <th style="text-align: left; padding: 2px;">Quantity</th> <th style="text-align: left; padding: 2px;">Amount</th> <th style="text-align: left; padding: 2px;">Sub-Total in USD(\$)</th> </tr> </thead> <tbody> <tr> <td>Basic Filing:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Pages:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Claims:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Miscellaneous-Filing:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Petition:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Patent-Appeals-and-Interference:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Post-Allowance-and-Post-Issuance:</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>					Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	Basic Filing:					Pages:					Claims:					Miscellaneous-Filing:					Petition:					Patent-Appeals-and-Interference:					Post-Allowance-and-Post-Issuance:				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)																																								
Basic Filing:																																												
Pages:																																												
Claims:																																												
Miscellaneous-Filing:																																												
Petition:																																												
Patent-Appeals-and-Interference:																																												
Post-Allowance-and-Post-Issuance:																																												
Utility Appl issue fee	1501	1	1400	1400																																								
Publ. Fee- early, voluntary, or normal	1504	1	300	300																																								

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1700